Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole

YEŞİL DEVECİOĞLU T., Aydogan F., Omurtag G. Z., Bese N. S., Sardas S.

NORTHERN CLINICS OF ISTANBUL, vol.5, no.1, pp.6-13, 2018 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 5 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.14744/nci.2017.55822
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.6-13
  • Istanbul University Affiliated: No


OBJECTIVE: Breast cancer is the most common cancer in women worldwide and the incidence increases in postmenopausal women. Anastrozole is a non-steroidal (type II), third-generation aromatase inhibitor (AI) that is used in the treatment of postmenopausal estrogen-related breast cancer. Several studies have been conducted to assess the efficacy, safety, and superiority of AIs to tamoxifen; however, a literature search did not reveal a study that investigated the genotoxic potential of AIs. The aim of this study was to investigate the possible DNA damage risk profile and individual DNA repair capacity of patients using anastrozole with the modified alkaline comet assay in order to contribute to public health and health economics.